奥曲肽治疗大肠癌伴肝脏转移随机对照探究.doc

奥曲肽治疗大肠癌伴肝脏转移随机对照探究[摘要] 目的 观察奥曲肽治疗大肠癌伴肝脏转移患者的的近期疗效、生活质量及生存时间。方法 30例大肠癌伴肝脏转移患者分为两组， 对照组（n=15）予全身化疗（FOLFOX4方案）及补液、对症及营养支持；观察组 （n=15）治疗方案在对照组基础上加用奥曲肽治疗，剂量为0.1mg，皮下注射， 每8小时1次。结果 对照组15例中PR 3例， SD 7例，PD 5例，有效率为20.00%；奥曲肽组15例中，PR 5例， SD 8例，PD 2例，有效率为33.33%。对照组生活质量改善4例，无变化3例，恶化8例，改善率26.67%；奥曲肽组显著改善1例，改善6例，无变化5例，恶化3例，改善率46.67%；两组改善率比较，差异有统计学意义（P＜0.05）。观察组的中位生存期（35.0±5.5）周显著长于对照组（23.0±3.8）周。结论 对大肠癌伴肝脏转移患者应用奥曲肽治疗， 近期疗效较好，无严重不良反应，可明显改善生活质量、延长生存时间。 [关键词] 奥曲肽；大肠癌；肝脏转移 [中图分类号] R735.3+4 [文献标识码] B [文章编号] 1673-9701（2011）24-89-02 Treatment of Colorectal Cancer Patients with Liver Metastasis with Octreotide：A Randomised Controlled Study TIAN Mengzi LIN Jianbo Department of General Surgery，Dongying Peoples Hospital，Dongying 257091，China [Abstract] Objective To observe the effective of octreotide for colorectal cancer patients with liver metastasis. Methods Thirty cases with colorectal cancer with liver metastasis were divided into two groups randomly. The control group （n=15） was administered systemic chemotherapy （FOLFOX4 scheme） and fluid infusion， and nutrition support； The observation group （n=15），based on the foregoing treatment，added octreotide（the dose was 0.1 mg， subcutaneous injection， every eight hours at one time）. Results In the control group，PR 3 cases，SD 7 cases， PD 5 cases， the effective rate was 20.00%. Octreotide group，PR 5 cases，SD 8 cases，PD 2 cases， the effective rate was 33.33%. In the control group，4 cases have improved quality of life，3 cases no change，8 cases deterioration， improvement rate 26.67%. Octreotide group，the quality of life is significantly improved in 1 case， and improved in 6，no change in 5， and deterioration in 3，improvement rate 46.67%； the difference was statistically significant （P＜0.05） between the two groups of improvement rate. The median survival of the octreotide group （35.0±5.5） weeks was significantly longer than that of the control group （23.0±3.8） weeks. Conclusion The administration in colorectal cancer patients with l